Lupin’s shares surged 2.2% to a day's high on September 25, after the USFDA approved its generic version of Gilead’s HIV drug, Biktarvy, in the US market worth $16.237 billion. The approval allows Lupin to market the medicine in the US, strengthening its antiviral portfolio. This could boost the company’s revenue and global presence in the fast-growing HIV treatment segment.